A comprehensive introduction to the indications and applicable patient groups of fezolinetant

Fezolinetant is a new type of non-hormonal selective neurokinin3(NK3) receptor antagonists, mainly used to treat moderate to severe vasomotor symptoms (VMS) in perimenopausal and postmenopausal women, such as hot flashes (hot flashes) and night sweats. These symptoms are often caused by fluctuations or decreases in estrogen levels, which can seriously affect a woman's quality of life. Compared with traditional hormone replacement therapy (HRT), filazonatant does not contain estrogen and is suitable for patients who are not suitable or unwilling to receive hormone therapy, providing a treatment option for a wider range of people.

In terms of indications, fezonatant is specifically used to treat vasomotor symptoms related to menopause, and is not used for other menopausal-related diseases such as osteoporosis, vaginal atrophy, etc. Its mechanism of action is to regulate the body temperature regulation center by blocking NK3 receptors in the hypothalamus of the brain, thereby reducing discomforts such as hot flashes and sweating caused by temperature regulation disorders. This mechanism provides a new treatment idea for non-hormonal drugs, and also allows it to be quickly recognized in clinical practice.

In terms of applicable populations, Fezonatant is particularly suitable for women who are unable to receive traditional hormone therapy due to high blood pressure, history of breast cancer, history of blood clots, or other hormone-related contraindications. In addition, for patients who have psychological concerns about hormone therapy and are concerned about the risk of breast cancer, filazonatant provides a safer, more compliant alternative. Studies have shown that filazonatant can significantly relieve hot flash symptoms and significantly improve sleep and mood within a few weeks of starting the medication.

In general, Fezonatant is a new drug with higher safety, faster onset of action, and no hormone structure. It is specially designed for women in the perimenopausal and postmenopausal stages who suffer from moderate to severe hot flashes or night sweats. For patient groups who cannot use hormone replacement therapy, it provides a clinically important alternative, which is expected to improve the quality of life of menopausal women and broaden the treatment path for menopausal management.

Reference materials:https://www.drugs.com/